Tirzepatide and semaglutide are popular weight loss drugs. Learn how they differ in effectiveness, cost, and side effects.

Doctronic reports new AI analysis reveals GLP-1 medications may cause underreported symptoms like menstrual irregularities and fatigue.

Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...

Mounjaro (tirzepatide) is a once-weekly injectable medicine that helps people with type 2 diabetes keep their blood sugar under control. It also causes weight loss. If you’ve seen the dramatic effects ...

People may react differently to GLP-1s due to factors like age, sex, and diet. Side effects, such as nausea and vomiting, are common with both semaglutide and tirzepatide. Starting with a low dose and ...

Although Mounjaro is not FDA-approved for weight loss, it contains the same active ingredient as Zepbound (tirzepatide), ...

Tirzepatide, the active ingredient in Zepbound and Mounjaro, is the first drug in a family of medicines that target two ...

Although semaglutide (Ozempic, Wegovy) and other GLP-1 drugs have rapidly become infamous for a wide variety of common side effects, from diarrhea to “Ozempic face,” the most prominent warnings on ...

When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction.

Tirzepatide (Mounjaro®, Zepbound®) can help people with type 2 diabetes manage their blood sugar levels and people with overweight or obesity lose weight. There are no guidelines saying you can’t ...

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...